SOD1 and amyotrophic lateral sclerosis: M102 treatment is a dual activator of the NRF2 and HSF1 pathways in ALS patient-derived iAstrocytes, and is sufficient to reduce oxidative stress, misfolded SOD1, and TDP-43 proteinopathy in vitro